Labcorp Rolls Out AI Platform to Accelerate Alzheimer's Research
HEALTH & BEAUTY
Platform leverages agentic AI and diverse healthcare datasets to transform and speed drug development.
Labcorp has introduced an AI-powered real-world data platform designed to transform how researchers and biopharmaceutical companies analyze Alzheimer's disease data. Developed in partnership with Amazon Web Services and Datavant, the platform aims to accelerate scientific discovery, shorten drug development timelines, and improve clinical trial patient recruitment.
The platform provides access to large, diverse datasets and advanced analytics using deidentified, privacy-protected healthcare data. Researchers can now generate insights in minutes that previously required months of intensive data mining.
Addressing a Critical Health Challenge
With more than 7.2 million Americans living with Alzheimer's disease and annual care costs exceeding $380 billion in the United States, accelerating drug development has become increasingly urgent. Traditional research has been hampered by fragmented data and lengthy data preparation processes that slow progress.
Labcorp's platform addresses these challenges by leveraging standardized laboratory data captured across millions of patients combined with advanced AI models to streamline data access and analysis. As a leader in neurology diagnostics, Labcorp offers the broadest blood-based biomarker testing portfolio for Alzheimer's disease and dementia, generating data that uniquely inform the depth, quality, and scale of insights produced through the platform.
"This platform represents a powerful acceleration in Alzheimer's research," said Bola Oyegunwa, Ph.D., Labcorp's Executive Vice President and Chief Information and Technology Officer. "By combining AI, advanced analytics and the scale of Labcorp's diagnostic data, we're redefining what's possible, compressing months of manual data preparation into minutes."
Comprehensive Data Integration
The platform represents a breakthrough in unifying healthcare research, combining Labcorp's extensive diagnostic and genomic datasets with medical claims data. Future versions will incorporate electronic health record and social determinants of health data. Powered by advanced AI analytics, including Amazon Bedrock agents and Amazon SageMaker, the platform can quickly identify patient cohorts, track disease progression patterns, and measure treatment effectiveness across diverse populations.
Dr. Rowland Illing, Chief Medical Officer and Director of Healthcare and Life Sciences at AWS, emphasized the platform's transformative potential. "This collaboration between Labcorp and AWS shows how AI can help reduce the time from hypothesis to actionable insight from months to minutes, potentially shaving years off the drug development process," he said.
Platform Capabilities
The platform's AI-powered analytics interface offers several key capabilities. It provides real-time, population-level analysis of treatment patterns, effectiveness, and patient outcomes across diverse populations. Researchers can characterize patient segments tested for Alzheimer's disease and identify deidentified patient cohorts suitable for clinical trial recruitment based on defined inclusion and exclusion criteria. The platform also includes advanced statistical modeling tools to identify patient cohorts with unmet clinical need.
Future Expansion Plans
The platform will complete its initial validation phase in spring 2026. Labcorp plans to expand the platform throughout 2026, incorporating additional data sources and analytical capabilities to accelerate research insights in other areas including inflammatory diseases, cardiometabolic conditions, women's health, and oncology.
This innovation extends Labcorp's broader real-world data strategy, leveraging AWS's AI-powered analytics and Datavant's privacy-preserving connectivity to enable secure, scalable analysis of deidentified healthcare data.
Labcorp, which trades on the New York Stock Exchange under the symbol LH, employs nearly 71,000 people serving clients in approximately 100 countries. The company supported more than 85 percent of new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests worldwide.